{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:07:55Z","timestamp":1788815275154,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272751"],"award-info":[{"award-number":["82272751"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021LSW002"],"award-info":[{"award-number":["ZR2021LSW002"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118366","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:21:28Z","timestamp":1786749688000},"page":"118366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["ABCB1 overexpression confers resistance to litronesib, an Eg5 inhibitor"],"prefix":"10.1016","volume":"253","author":[{"given":"Yong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheshen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexiazi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letao","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118366_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2026.118366_b0010","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2026.118366_b0015","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1126\/science.add9528","article-title":"Control of cell proliferation by memories of mitosis","volume":"383","author":"Meitinger","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118366_b0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41586-023-06085-6","article-title":"Mitotic bookmarking by SWI\/SNF subunits","volume":"618","author":"Zhu","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118366_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101223","article-title":"Novel insights into taxane pharmacology: an update on drug resistance mechanisms, immunomodulation and drug delivery strategies","volume":"81","author":"Beretta","year":"2025","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100849","article-title":"New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects","volume":"64","author":"Huang","year":"2022","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0035","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41418-021-00899-5","article-title":"NAT10 regulates mitotic cell fate by acetylating Eg5 to control bipolar spindle assembly and chromosome segregation","volume":"29","author":"Zheng","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2026.118366_b0040","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/3649912","article-title":"Eg5 and diseases: from the well-known role in cancer to the less-known activity in noncancerous pathological conditions","volume":"2024","author":"Ricci","year":"2024","journal-title":"Biochem. Res. Int."},{"key":"10.1016\/j.bcp.2026.118366_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202115846","article-title":"Optical control of mitosis with a photoswitchable Eg5 inhibitor","volume":"61","author":"Impastato","year":"2022","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118366_b0050","article-title":"Morphological profiling identifies the motor protein Eg5 as cellular target of spirooxindoles","volume":"62","author":"Liu","year":"2023","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118366_b0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12974-023-02822-w","article-title":"Kinesin-5 inhibition improves neural regeneration in experimental autoimmune neuritis","volume":"20","author":"Kohle","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bcp.2026.118366_b0060","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.1021\/acs.jmedchem.1c02001","article-title":"Ispinesib as an effective warhead for the design of autophagosome-tethering chimeras: discovery of potent degraders of nicotinamide phosphoribosyltransferase (NAMPT)","volume":"65","author":"Dong","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118366_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.02.016","article-title":"KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo","volume":"506","author":"Jungwirth","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.118366_b0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10637-007-9098-8","article-title":"Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"26","author":"Tang","year":"2008","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2026.118366_b0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-019-0240-6","article-title":"A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"9","author":"Lee","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcp.2026.118366_b0080","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.2174\/1871520622666220119093105","article-title":"Role of KSP inhibitors as anti-cancer therapeutics: an update","volume":"22","author":"Chamariya","year":"2022","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bcp.2026.118366_b0085","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2174\/0127724328277623231204064614","article-title":"The application of kinesin inhibitors in medical issues","volume":"19","author":"Nejabat","year":"2024","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118366_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100754","article-title":"Therapeutic strategies to overcome taxane resistance in cancer","volume":"55","author":"Das","year":"2021","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100905","article-title":"ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance","volume":"66","author":"Fan","year":"2023","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101058","article-title":"Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy","volume":"73","author":"To","year":"2024","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101016","article-title":"Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance","volume":"72","author":"Zhu","year":"2024","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101004","article-title":"Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer","volume":"71","author":"Bharathiraja","year":"2023","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060334","article-title":"Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference","volume":"8","author":"Ansbro","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118366_b0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00210-005-0022-5","article-title":"Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein","volume":"372","author":"Peters","year":"2006","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118366_b0125","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/1535-7163.MCT-09-1103","article-title":"Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition","volume":"9","author":"Wiltshire","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118366_b0130","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118366_b0135","doi-asserted-by":"crossref","DOI":"10.1126\/science.adj4591","article-title":"Structure and function of the Arabidopsis ABC transporter ABCB19 in brassinosteroid export","volume":"383","author":"Ying","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118366_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101065","article-title":"ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C","volume":"73","author":"Lei","year":"2024","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0145","first-page":"288","article-title":"RN486, a Bruton\u2019s Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells","volume":"12","author":"Dong","year":"2024","journal-title":"J. Transl. Int. Med."},{"key":"10.1016\/j.bcp.2026.118366_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101028","article-title":"Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor","volume":"73","author":"Teng","year":"2024","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217309","article-title":"Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies","volume":"607","author":"Dong","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.118366_b0160","article-title":"Reversal of ABCG2-mediated drug resistance by tinodasertib (ETC-206)","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118366_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101202","article-title":"Peptide-based PET\/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma","volume":"79","author":"Wang","year":"2025","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101100","article-title":"Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration","volume":"76","author":"Ji","year":"2024","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.bcp.2026.118366_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114364","article-title":"Eg5 targeting agents: from new anti-mitotic based inhibitor discovery to cancer therapy and resistance","volume":"184","author":"Garcia-Saez","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118366_b0180","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1021\/jm800386y","volume":"51","author":"Cox","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118366_b0185","first-page":"87","article-title":"Drug targets and resistance mechanisms in multiple myeloma","volume":"1","author":"Nass","year":"2018","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.bcp.2026.118366_b0190","article-title":"In vivo reversal of P-glycoprotein-mediated drug resistance in a breast cancer xenograft and in leukemia models using a novel, potent, and nontoxic epicatechin EC31","volume":"24","author":"Sun","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118366_b0195","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1038\/s41380-022-01733-1","article-title":"ABCB1 variants and sex affect serotonin transporter occupancy in the brain","volume":"27","author":"Silberbauer","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.bcp.2026.118366_b0200","first-page":"e427","article-title":"Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy","volume":"2023","author":"Cao","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.bcp.2026.118366_b0205","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2478\/jtim-2024-0025","article-title":"Actin-related protein 2\/3 complex subunit 1B promotes ovarian cancer progression by regulating the AKT\/PI3K\/mTOR signaling pathway","volume":"12","author":"Ke","year":"2024","journal-title":"J. Transl. Int. Med."},{"key":"10.1016\/j.bcp.2026.118366_b0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00280-014-2467-z","article-title":"A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors","volume":"74","author":"Wakui","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118366_b0215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00280-016-3205-5","article-title":"Two phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer","volume":"79","author":"Infante","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118366_b0220","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s10637-011-9653-1","article-title":"A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors","volume":"30","author":"Holen","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2026.118366_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.143158","article-title":"Structural and functional impacts of charge modification in Chondroitinase ABC I","volume":"309","author":"Haghnazari","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.118366_b0230","first-page":"37","article-title":"A phase 1 dose-escalation study of LH031, a kinesin spindle protein inhibitor, in patients with refractory\/resistant multiple myeloma","volume":"136","author":"Xia","year":"2020","journal-title":"Blood"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:16:54Z","timestamp":1788812214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226007057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":46,"alternative-id":["S0006295226007057"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118366","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ABCB1 overexpression confers resistance to litronesib, an Eg5 inhibitor","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118366"}}